Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction

Heart failure (HF), with steadily increasing incidence rates and mortality in an ageing population, represents a major challenge. Evidence suggests that more than half of all patients with a diagnosis of HF suffer from HF with preserved ejection fraction (HFpEF). Emerging novel biomarkers to improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Zach, Veronika, Bähr, Felix Lucas, Edelmann, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Radcliffe Cardiology 2020
Materias:
Ejection Fraction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111301/
https://www.ncbi.nlm.nih.gov/pubmed/32257387
http://dx.doi.org/10.15420/cfr.2019.10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7111301/
https://www.ncbi.nlm.nih.gov/pubmed/32257387
http://dx.doi.org/10.15420/cfr.2019.10

Ejemplares similares